scholarly journals A Case of Spontaneous Tumor Lysis Syndrome in a Patient with Ovarian Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Kazuhiro Okamoto ◽  
Toshifumi Kinoshita ◽  
Miyuki Shimizu ◽  
Isoji Okura ◽  
Akinori Kawada ◽  
...  
Keyword(s):  
Ovarian Tumor ◽  
Tumor Recurrence ◽  
Hematological Malignancies ◽  
Tumor Lysis Syndrome ◽  
Anticancer Therapy ◽  
The Novel ◽  
Chemotherapy Treatment ◽  
Tumor Lysis ◽  
Life Threatening ◽  
Spontaneous Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) is a potentially life-threating complication of tumors or chemotherapy treatment. TLS commonly occurs in hematological malignancies, but it is very rare in patients with a solid tumor. In cases of solid tumors, TLS usually occurs spontaneously and after the initiation of anticancer therapy, and it has a high mortality rate. We present the novel case of a 62-year-old woman with an ovarian tumor who spontaneously developed TLS. Surgical reduction of the tumor mass vastly improved her condition. She showed no sign of tumor recurrence 8 months after treatment. As TLS is life-threatening, successful treatments must be seriously considered.

scholarly journals Fatal Spontaneous Tumor Lysis Syndrome in a Patient with Metastatic Colon Cancer: A Clinical Case of Rare Oncological Emergency

2020 ◽  
Vol 14 (2) ◽  
pp. 255-260
Author(s):  
Inna Shaforostova ◽  
Robert Fiedler ◽  
Martina Zander ◽  
Johannes Pflumm ◽  
Wolfgang Josef März
Keyword(s):  
Colon Cancer ◽  
Case Reports ◽  
Multiorgan Failure ◽  
Tumor Lysis Syndrome ◽  
Metastatic Colon Cancer ◽  
Tumor Lysis ◽  
Oncological Emergency ◽  
Electrolyte Disturbances ◽  
Life Threatening ◽  
Spontaneous Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) is a potentially life-threatening complication of chemotherapy. It usually occurs in rapidly proliferating hematological malignancies. TLS is deemed spontaneous (STLS) when it occurs prior to any cytotoxic or definite treatment. STLS is extremely rare in solid tumors. Here, we report a rare case of fatal STLS in a 47-year-old woman diagnosed with metastatic colon cancer. The patient developed acute renal failure with anuria, electrolyte disturbances, and metabolic acidosis before initiating chemotherapy. Despite appropriate management of TLS, including renal replacement therapy, she died within a few days from multiorgan failure. Only few other case reports of STLS associated with colon cancer have been reported in the literature.

From skin to spontaneous lysis: A case of spontaneous tumor lysis syndrome in metastatic melanoma

2017 ◽  
Vol 24 (3) ◽  
pp. 221-225 ◽  
Author(s):  
Charis G Durham ◽  
Jon Herrington ◽  
Susan Seago ◽  
Chelsea Williams ◽  
Mark H Holguin
Keyword(s):  
Metastatic Melanoma ◽  
Rare Case ◽  
Tumor Lysis Syndrome ◽  
Cytotoxic Therapy ◽  
Acute Leukemias ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Life Threatening ◽  
Spontaneous Tumor Lysis Syndrome ◽  
Life Threatening Complication

Tumor lysis syndrome is a life-threatening complication that often occurs after administration of cytotoxic therapy, but rarely occurs spontaneously without chemotherapy. This vignette describes a 59-year-old male with known extensive metastatic melanoma who presented to the hospital with spontaneous tumor lysis syndrome. Most spontaneous tumor lysis cases occur in patients with acute leukemias and aggressive lymphomas; however, this rare case depicts a patient with melanoma developing tumor lysis before the administration of chemotherapy.

scholarly journals Acute Tumor Lysis Syndrome: A Metabolic Emergency in Cancer Patients

2021 ◽  
Vol 14 (3) ◽  
pp. 1721-1729
Author(s):  
Giorgio Attinà ◽  
Raffaele Tepedino ◽  
Antonio Ruggiero
Keyword(s):  
Lymphoblastic Leukemia ◽  
Tumor Lysis Syndrome ◽  
Therapeutic Strategies ◽  
Chemotherapy Treatment ◽  
Cytotoxic Therapy ◽  
Tumor Lysis ◽  
Rapid Release ◽  
Life Threatening ◽  
Life Threatening Complication ◽  
Massive Cell

Tumor lysis syndrome (TLS) can be a life-threatening complication that occurs following the onset of chemotherapy treatment, most commonly in association with high-grade lymphoproliferative pathologies such as acute lymphoblastic leukemia and Burkitt lymphoma. The massive cell lysis caused by cytotoxic therapy leads to the rapid release in the blood of intracelullary products and the onset of severe metabolic and electrolytic complications (hyperkalemia, hyperphosphatemia, hypocalcemia and hyperuricemia) upto the acute renal failure. This article describes the incidence and pathophysiological basis of TLS, focusing on the new therapeutic strategies implemented over the last few years, especially with regard to the treatment of hyperuricemia. In particular, it highlights the characteristics of a recent drug, Rasburicase, as a safe and effective alternative, compared to traditional allopurinol therapy, for prophylaxis and treatment of children with hyperuricemia induced by chemotherapy.

Spontaneous clinical tumor lysis syndrome in solid renal tumor: first case report in non-metastatic renal carcinoma

2020 ◽  
Vol 4 (3) ◽  
pp. 124-127
Author(s):  
Bruno Nogueira Cesar ◽  
Nilo Eduardo Delboni Nunes ◽  
Maria Amelia Aguiar Hazin ◽  
Renato Demarchi Foresto ◽  
Gianna Mastroianni Kirsztajn ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Lysis Syndrome ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
First Case ◽  
Spontaneous Tumor Lysis Syndrome ◽  
Hematological Tumors

Spontaneous tumor lysis syndrome is a rare emergency in onco-nephrology that results from extensive cancer cell lysis independent of antitumoral therapy. It is common among hematological tumors and can be rarely seen with solid tumors. In medical literature, there is only one case report with spontaneous tumor lysis syndrome in renal cell carcinoma and it was associated with metastases. To the best of our knowledge, this is the first report of spontaneous tumor lysis syndrome in non-metastatic renal cell carcinoma.

scholarly journals The Domino Effect-Treatment of Superior Vena Cava Obstruction Triggering Tumor Lysis Syndrome: A Case Report

2021 ◽  
Vol 3 (1) ◽  
pp. 44-50
Author(s):  
Suman Ghosh ◽  
Tilak TVSVGK ◽  
Venkatesan Somasundaram ◽  
Mutreja Deepti
Keyword(s):  
Superior Vena Cava ◽  
Lymphoblastic Leukemia ◽  
Superior Vena ◽  
Tumor Lysis Syndrome ◽  
Vena Cava ◽  
Potassium Phosphate ◽  
Successful Outcome ◽  
Superior Vena Cava Obstruction ◽  
Tumor Lysis ◽  
Life Threatening

Oncological emergencies present in a multitude of manners-structural, metabolic, hematologic, etc. affecting multiple systems, often. Urgent institution of therapy is often required for a successful outcome. Occasionally, the treatment of one emergency can initiate a related or unrelated emergency, necessitating management of all the complications simultaneously. Superior vena cava obstruction (SVCO) is a medical emergency and most often manifests in patients with a malignant disease process requiring immediate diagnostic evaluation and therapy due to its’ life threatening presentation. The management of the SVCO is usually with chemotherapy, radiotherapy or intervention. In cases of large tumor burden, management of SVCO can trigger other complications. Tumor lysis syndrome is an oncologic emergency, which is characterized by a massive release of intracellular potassium, phosphate, and nucleic acid metabolites into the systemic circulation, which can be life-threatening. We present the case of a T-cell acute lymphoblastic leukemia with superior vena cava syndrome, developing tumor lysis syndrome on instituting definitive chemotherapy in a young patient. Doi: 10.28991/SciMedJ-2021-0301-6 Full Text: PDF

scholarly journals A Case of Spontaneous Tumor Lysis Syndrome in Malignant Melanoma

2016 ◽  
Vol 7 (2-3) ◽  
pp. 40-44 ◽  
Author(s):  
Nobumichi Takeuchi ◽  
Shun Miyazawa ◽  
Zentaro Ohno ◽  
Sonomi Yoshida ◽  
Tetsu Tsukamoto ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Tumor Lysis Syndrome ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Spontaneous Tumor Lysis Syndrome

Hematologic and Oncologic Emergencies

2019 ◽  
pp. 170-177
Author(s):  
James McCue
Keyword(s):  
Emergency Department ◽  
Standardized Tests ◽  
Tumor Lysis Syndrome ◽  
Clinical Effects ◽  
Tumor Lysis ◽  
Oncologic Emergencies ◽  
First Response ◽  
Appropriate Treatment ◽  
Wide Range ◽  
Life Threatening

Hematologic and oncologic emergencies are an uncommon reason for people to present to the emergency department (ED), but when they do, it is important to know how to diagnose and treat these conditions because many of them are life threatening. Whether it is bleeding due to conditions such as hemophilia, von Willebrand’s disease, warfarin use, or dangerous conditions related to cancer such as tumor lysis syndrome or neutropenic fever, knowing the basics will help you manage these patients and also ace the standardized tests. This chapter presents questions related to the diagnosis, clinical effects, best first response in the ED, and most appropriate treatment of a wide range of these hematologic and oncologic emergencies.

scholarly journals Spontaneous Tumor Lysis Syndrome in Blastoid-Variant Mantle Cell Lymphoma: Considerations for the General Internist

2020 ◽  
Vol 8 ◽  
pp. 232470962094470 ◽  
Author(s):  
Vishal Patel ◽  
Robert Case
Keyword(s):  
Uric Acid ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Tumor Lysis Syndrome ◽  
General Internist ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Mantle Cell ◽  
Spontaneous Tumor Lysis Syndrome

Spontaneous tumor lysis syndrome (SPTLS) is a rare phenomenon that can manifest in rapidly proliferating hematological malignancies and solid tumors prior to initiating cytotoxic therapy. We encountered a patient who originally presented with diffuse lymphadenopathy, abdominal distention, and dyspnea, who had laboratory abnormalities suggestive of SPTLS. His peripheral flow cytometry and lymph node biopsy revealed blastoid-variant mantle cell lymphoma. Prior to initiating chemotherapy, acute kidney injury (AKI) and uric acid had improved with intravenous fluids and the initiation of allopurinol. However, after beginning chemotherapy, the patient developed a second AKI concerning for tumor lysis syndrome (TLS). He went on to have renal recovery and did not require renal replacement therapy. With the exception of case reports, there is limited evidence to guide general medicine clinicians who encounter cases of SPTLS. Expert-based guidelines are available to guide use of rasburicase, an uricase enzyme, before initiation of chemotherapy for certain malignancies when risk for TLS is considered high. Despite these guidelines, the role of rasburicase in preventing AKI remains controversial after inconclusive results in a meta-analysis. The causative relationship between uric acid and AKI in TLS is based on a mechanism of tubular obstruction. There are also mechanisms by which uric acid may cause AKI without tubular obstruction related to acute hyperuricemic nephropathy. Further characterization of the role of uric acid in causing AKI in patients without tubular obstruction may identify new mechanisms of injury and offer insight into new treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document